Prime Medicine, Inc.

Healthcare

NASDAQ:PRME · NASDAQ Global Market

Market Cap $570.75M Beta 2.31 P/E (TTM) -2.8

$3.23 -1.11%

-$0.04 today

52W Low $1.77High $6.94

Vol 3.19M · Avg 2.47M

EPS (TTM) -$1.12Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+49.54%

Period High

$6.67

Period Low

$2.16

Latest

$3.23

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Tyra Biosciences, Inc.

NASDAQ:TYRA

$1.68B

Septerna, Inc.

NASDAQ:SEPN

$1.59B

Vir Biotechnology, Inc.

NASDAQ:VIR

$1.54B

Bicara Therapeutics Inc. Common Stock

NASDAQ:BCAX

$1.27B

EyePoint Pharmaceuticals, Inc.

NASDAQ:EYPT

$1.12B

Kura Oncology, Inc.

NASDAQ:KURA

$857.93M

Replimune Group, Inc.

NASDAQ:REPL

$836.46M

Maravai LifeSciences Holdings, Inc.

NASDAQ:MRVI

$729.83M

Rezolute, Inc.

NASDAQ:RZLT

$487.24M

ProKidney Corp.

NASDAQ:PROK

$261.51M

What is the latest PRME filing?

The latest filing shown is 485BXT dated Jun 18, 2026.

How many recent filings does PRME have?

Intrinsic Alpha currently shows 20 recent filings for PRME.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.